Clinical Immunology and Multiplex Biomarkers of Human Tuberculosis

Walzl, Gerhard; Haks, Mariëlle C.; Joosten, Simone A.; Kleynhans, Léanie; Ronacher, Katharina; Ottenhoff, Tom H. M.

doi:10.1101/cshperspect.a018515

Cited by 34 publications

(35 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While confirming the presence of most described signatures in multiple studies, their study identified a hitherto underappreciated role of the Bcell compartment. The results also point to an involvement of TREM1 signaling in active TB disease, something that had not been described in any of the previous studies separately (see also Walzl et al 2014). Shortly after, Cliff et al (2013) also identified significant changes in expression of a network of B-cell-related genes during disease resolution.…”

Section: Genetic Biosignatures In Tb Diseasesupporting

confidence: 68%

Toward a Unified Biosignature for Tuberculosis

Maertzdorf

Kaufmann

Weiner

2014

Cold Spring Harbor Perspectives in Medicine

View full text Add to dashboard Cite

Accurate and rapid diagnosis of active tuberculosis (TB) disease is still hampered by inadequate tools. Although current assays relying on single-marker readouts mostly display inadequate sensitivity and/or specificity, host-related multimarker signatures are especially poorly developed. As a consequence, research programs have been initiated to search for combinations of markers-so-called biosignatures with superior performance. Many such investigations harness high-throughput platforms to analyze the host response during infection and disease. A major challenge for these activities is the analysis of vast amounts of data produced. Specialized bioinformatic tools are being applied to identify the most robust biosignatures for classification of exposed and diseased individuals and prognosis of risk of disease in endemic areas. Validation of the most promising biosignatures in ongoing multicohort studies will bring us a step closer to the identification of an accurate unified signature.

show abstract

Section: Genetic Biosignatures In Tb Diseasesupporting

confidence: 68%

Toward a Unified Biosignature for Tuberculosis

Maertzdorf

Kaufmann

Weiner

2014

Cold Spring Harbor Perspectives in Medicine

View full text Add to dashboard Cite

show abstract

“…However, due to the complexity of tuberculosis associated diseases, for example with HIV, where the lung pathology can differ from that in the immune-competent host, these biomarkers would have to be validated in these broader contexts as well. Finally, these biomarkers are not only very important for TB as diagnostic tools and treatment, but also might reveal new candidates for the development and evaluation of new vaccines against tuberculosis [74].…”

Section: Discussionmentioning

confidence: 99%

Immunomodulating microRNAs of mycobacterial infections

2016

View full text Add to dashboard Cite

“…Clinical trials that evaluate new anti-tubercular drugs and treatment regimens take years to complete due to the slow clearance of Mycobacterium tuberculosis infection and the lack of early biomarkers that predict treatment outcome [4,5]. Persistence of positive cultures at month 2 of anti-tubercular treatment (ATT) has been proposed as predictor for treatment failure and relapse [6].…”

Section: Introductionmentioning

confidence: 99%

Sustained elevated levels of C-reactive protein and ferritin in pulmonary tuberculosis patients remaining culture positive upon treatment initiation

et al. 2017

View full text Add to dashboard Cite

BackgroundClinical trials that evaluate new anti-tubercular drugs and treatment regimens take years to complete due to the slow clearance of Mycobacterium tuberculosis infection and the lack of early biomarkers that predict treatment outcomes. Host Inflammation markers have been associated with tuberculosis (TB) pathogenesis. In the present study, we tested if circulating levels of C-reactive protein (CRP) and ferritin reflect mycobacterial loads and inflammation in pulmonary TB (PTB) patients undergoing anti-tuberculous therapy (ATT).MethodsProspective measurements of CRP and ferritin, used as readouts of systemic inflammation, were performed in cryopreserved serum samples from 165 Brazilian patients with active PTB initiating ATT. Associations between levels of these laboratory parameters with mycobacterial loads in sputum as well as with sputum conversion at day 60 of ATT were tested.ResultsCirculating levels of both ferritin and CRP gradually decreased over time on ATT. At pre-treatment, concentrations of these parameters were unable to distinguish patients with positive from those with negative acid-fast bacilli (AFB) in sputum cultures. However, patients who remained with positive cultures at day 60 of ATT exhibited heightened levels of these inflammatory markers compared to those with negative cultures at that time point.ConclusionsCRP and Ferritin levels in serum may be useful to identify patients with positive cultures at day 60 of ATT.

show abstract

Clinical Immunology and Multiplex Biomarkers of Human Tuberculosis

Cited by 34 publications

References 73 publications

Toward a Unified Biosignature for Tuberculosis

Toward a Unified Biosignature for Tuberculosis

Immunomodulating microRNAs of mycobacterial infections

Sustained elevated levels of C-reactive protein and ferritin in pulmonary tuberculosis patients remaining culture positive upon treatment initiation

Contact Info

Product

Resources

About